Category Archives: Adult Stem Cells

Maltese abroad: the best-selling author with roots in Gozo – Times of Malta

Marianne Curley is a Maltese-Australian author best known for her Guardians of Time Trilogy and Old Magic books. She has had to overcome tremendous difficulties that are of inspiration to many.

My Dad was born in Gozo and moved to Australia when he was only 15. He eventually settled on the Hawkesbury River in New South Wales. He returned to Gozo when the war ended and met my mother. They married within three months and moved to Australia.

Mum became homesick and they moved back. But Dad was a farmer and longed for the open spaces and green fields of Australia. In August of 1957, as a family of five, they returned to the Hawkesbury River property. Two years later I was born.

My teen daughters asked me to write a book for their age. I had attempted to write commercial romance, with no success. I was about to start another romance when my thirteen-year-old daughter complained there were not enough books for her age to read. Her sister, older by one year, agreed and that is how I started writing books for young adults.

I found I loved writing for young adults. It was challenging and exciting with more complex plot lines and themes I could explore, and young adult readers appeared to enjoy my writing style.

I find inspiration almost anywhere if Im looking for it. I listen to music, look through photographs or glance at passing scenery in a car or train. Our world is full of ideas. They surround us wherever we go.

The plot for Old Magic, my first published novel, came to me while I was having lunch in a park with friends on Dorrigo Mountain. Our children were walking across a field together when a mist rolled in from behind them. I watched as the mist caught up and continued to roll past, making the children almost invisible. It struck me how magical the scene was.

My readers are my proudest achievements, through their emails and messages, that have given many reasons to be most proud of them. My readers have let me know how my books, the characters and stories within, have affected them, inspired them, assisted them in tough times, and changed their lives.

Surviving my type of cancer was a miracle that I thank God for every day. The odds were not in my favour, I had a 30-35 per cent chance of surviving, and without a successful transplant I would have died within two months of my diagnosis. I am thankful for my sister Therese for giving me her stem cells and for the prayers and support I received from my friends and relatives.

I could not write for years. Weeks after surviving my transplant, and on the way to recovering, I sustained a fall in my hospital room, that broke my back. My bones were week from the chemotherapy, my spine crumbled, and I lost several vertebrae. My spine wasnt strong enough for any supportive treatment. The pain when I moved was unimaginable. Because of this, I was unable to write again for a few years.

Only focus on today. Whatever you are facing, life can become complex and at times overwhelming. You think you cant cope. Dont think of all you have yet to do, just think about what you have to do today. Only today. Tomorrow will come, theres no doubt about that. Think of what you must do tomorrow, when it is tomorrow.

I dream of visiting Malta. I had planned to visit Malta as a reward after my cancer battle, but by then Id had the fall which made travelling difficult. So sadly, Ive never had the chance to visit Malta, which just makes me miss it more. My hope is that one day I can overcome my physical difficulties enough for a long visit.

Are you a Maltese person living abroad? Contact malteseabroad@timesofmalta.com

Continued here:
Maltese abroad: the best-selling author with roots in Gozo - Times of Malta

Early Results Are Positive for Experimental CRISPR Therapies – The Scientist

The first patients in each of two early-stage clinical trials testing CRISPR-based treatments for inherited blood disorders have been symptom free for several months with normalized hemoglobin levels, the companies developing the therapies announced today (November 19). Both participants experienced only treatable, temporary side effects, according to the data.

Last fall, Switzerland-headquartered CRISPR Therapeutics and Vertex Pharmaceuticals in Boston teamed up to launch a trial in Germany testing a CRISPR-based approach to treating -thalassemia. The therapy, known as CTX001, is applied to blood stem cells removed from the patient to cleave the BCL11A gene that represses the production of fetal hemoglobin. These cells are then reinfused to provide a healthy supply this protein, normally only produced in infancy, to overcome problems associated with mutations in the gene encoding the adult version. A few months later, the two companies launched a parallel trial in Nashville, Tennessee, to test CTX001 in sickle cell patients, who also suffer from mutations in the gene for adult hemoglobin.

The data released this week pertains to the first patients treated, one in each of these trials. In both participants, the CRISPRed cells successfully homed to the bone marrow. In the nine months since she received the treatment, the -thalassemia patient has required no blood transfusions, which she had needed regularly for 16 years, and her total hemoglobin levels are near-normal, STATreports. Meanwhile, the sickle-cell patient has not suffered any of the painful and organ-damaging events known as vaso-occlusive crises, where the misshapen blood cells characteristic of the disease stick to and clog small blood vessels, since she received her treatment in July, and her total hemoglobin levels have also normalized, according to STAT.

We are very, very excited, Haydar Frangoul, the treating physician at the Sarah Cannon Research Institute in Nashville, tells NPR. This preliminary data shows for the first time that gene editing has actually helped a patient with sickle cell disease. This is definitely a huge deal.

Both patients experienced only minimal side effects, which the treating physicians attributed to the drug busulfan, used to wipe out the patients mutant bone marrow cells before receiving the infusion of CRISPRed blood stem cells.

These results are remarkable because they represent the first clinical evidence that CRISPR-Cas9 has real curative potential, Jeff Leiden, the president and chief executive officer of Vertex Pharmaceuticals, tells STAT. Vertex and CRISPR Therapeutics say they will now proceed with enrolling a total of 45 patients in each trial.

Jef Akst is managing editor ofThe Scientist. Email her atjakst@the-scientist.com.

See the article here:
Early Results Are Positive for Experimental CRISPR Therapies - The Scientist

CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL – Lymphoma Hub

On the 14th November 2019, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of polatuzumab vedotin, in combination with bendamustine and rituximab (BR), for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are unsuitable for a hematopoietic stem cell transplant.1 Polatuzumab vedotin is a first-in-class anti-CD79b antibody-drug conjugate, which kills malignant B cells by delivering anti-mitotic monomethyl auristatin E.2

The combination was approved earlier this year by the U.S. Food and Drug Administration(FDA) for the treatment of patients with DLBCL (read more here).

The CHMPs positive opinion was based on data from the global phase Ib/II study GO29365 (NCT02257567) that evaluated the safety, tolerability, and activity of polatuzumab vedotin in combination with BR or obinutuzumab in R/R follicular lymphoma or DLBCL. The polatuzumab vedotin-BR combination achieved a complete response rate of 40% (n= 16/40) compared with 17.5% (n= 7/40) with BR alone, and a median survival of 12.4 months versus 4.7 months, respectively.3,4

See original here:
CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL - Lymphoma Hub

CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib – PRNewswire

SUZHOU, China, Nov. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616)today announced that the first patient has been dosed in the Phase I bridging registrational study of ivosidenib (TIBSOVO) in China. This stand-alone trial is designed to validate the efficacy, safety, and pharmacokinetics of ivosidenib in patients with IDH1 mutant relapsed or refractory acute myeloid leukemia (R/R AML).

Developed by CStone's partner, Agios Pharmaceuticals (NASDAQ: AGIO), ivosidenib was approved by the U.S. FDA in July 2018 for the treatment of adult patients with R/R AML with a susceptibleIDH1 mutation as detected by an FDA-approved test. In May 2019, CStone submitted a new drug application (NDA) for ivosidenib in Taiwan for the treatment of adult patients with IDH1 mutant R/R AML.

Current standard of care treatment for newly diagnosed AML patients mainly includes intensive induction chemotherapy (IC), followed by consolidation therapy such as allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in order to attain durable remission. Approximately 35% to 40% of those treated patients achieve complete remission, while only about 25% achieve 3 years or longer survival. The majority of AML patients develop acquired resistance to treatment or eventually relapse, leading to R/R AML, which has a very poor prognosis in the absence of standard of care treatment options globally. With the emergence of DNA sequencing technology, the detection of genetic mutations has presented new opportunities and challenges in AML treatment. IDH1 mutations are associated with around 6% to 10% of all AML cases.

Dr. Frank Jiang, Chairman and CEO of CStone, commented: "AML is the most common acute leukemia affecting adults with over 30,000 new cases estimated in China every year. AML is characterized by its rapid progression witha five-year survival rate below 20%. We are faced with the urgent need for clinical development, particularly for IDH1 mutant R/R AML patients, due to the lack of any effective treatment in China. We will rigorously press ahead with the clinical development of ivosidenib to achieve its regulatory approval in China which will allow more AML patients in Greater China to benefit from this precision therapy."

CStone's Chief Medical Officer, Dr. Jason Yang, noted: "Ivosidenib is a potent and highly selective IDH1 inhibitor, and the only targeted therapy currently approved by the U.S. FDA for IDH1 mutant AML. It is very encouraging that we have already initiated two registrational studies of ivosidenib in China, including the global Phase III AGILE study of ivosidenib in combination with azacitidinein adult patients with newly diagnosed IDH1 mutant AML who are not eligible for intensive chemotherapy."

About TIBSOVO (ivosidenib)

TIBSOVO is indicated for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in:

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome: See Boxed WARNING. In the clinical trial, 25% (7/28) of patients with newly diagnosed AML and 19% (34/179) of patients with relapsed or refractory AML treated with TIBSOVO experienced differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. Symptoms of differentiation syndrome in patients treated with TIBSOVO included noninfectious leukocytosis, peripheral edema, pyrexia, dyspnea, pleural effusion, hypotension, hypoxia, pulmonary edema, pneumonitis, pericardial effusion, rash, fluid overload, tumor lysis syndrome, and creatinine increased. Of the 7 patients with newly diagnosed AML who experienced differentiation syndrome, 6 (86%) patients recovered. Of the 34 patients with relapsed or refractory AML who experienced differentiation syndrome, 27 (79%) patients recovered after treatment or after dose interruption of TIBSOVO. Differentiation syndrome occurred as early as 1 day and up to 3 months after TIBSOVO initiation and has been observed with or without concomitant leukocytosis.

If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement. If concomitant noninfectious leukocytosis is observed, initiate treatment with hydroxyurea or leukapheresis, as clinically indicated. Taper corticosteroids and hydroxyurea after resolution of symptoms and administer corticosteroids for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid and/or hydroxyurea treatment. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt TIBSOVO until signs and symptoms are no longer severe.

QTc Interval Prolongation:Patients treated with TIBSOVOcan develop QT (QTc) prolongation and ventricular arrhythmias. One patient developed ventricular fibrillation attributed to TIBSOVO. Concomitant use of TIBSOVOwith drugs known to prolong the QTc interval (e.g., anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or in those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary.

Interrupt TIBSOVOif QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVOif QTc increases to greater than 500 msec. Permanently discontinue TIBSOVOin patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.

Guillain-Barr Syndrome:Guillain-Barr syndrome occurred in <1% (2/258) of patients treated with TIBSOVO in the clinical study. Monitor patients taking TIBSOVO for onset of new signs or symptoms of motor and/or sensory neuropathy such as unilateral or bilateral weakness, sensory alterations, paresthesias, or difficulty breathing. Permanently discontinue TIBSOVO in patients who are diagnosed with Guillain-Barr syndrome.

ADVERSE REACTIONS

DRUG INTERACTIONS

Strong or Moderate CYP3A4 Inhibitors:Reduce TIBSOVOdose with strong CYP3A4 inhibitors. Monitor patients for increased risk of QTc interval prolongation.

Strong CYP3A4 Inducers:Avoid concomitant use with TIBSOVO.

Sensitive CYP3A4 Substrates:Avoid concomitant use with TIBSOVO.

QTc Prolonging Drugs:Avoid concomitant use with TIBSOVO. If co-administration is unavoidable, monitor patients for increased risk of QTc interval prolongation.

LACTATION

Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVOand for at least 1 month after the last dose.

Please see full Prescribing Information, including Boxed WARNING.

About CStone

CStone Pharmaceuticals (HKEX:2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, five late-stage candidates are at or near pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone Pharmaceuticals, please visit: http://www.cstonepharma.com.

Forward-looking Statement

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

SOURCE CStone Pharmaceuticals

http://www.cstonepharma.com

See more here:
CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - PRNewswire

Redding woman donates bone marrow, saves life of a father – FOX61 Hartford

Please enable Javascript to watch this video

A 25-year-old Redding, Connecticut woman meets the Arizona man who was battling deadly Acute Lymphoblastic Leukemia (ALL) until she saved his life by donating her bone marrow.

Jennie Bunce joined Gift of Life Marrow Registry through a sorority swab drive at North Carolinas High Point University in 2016. "I can remember being like 13 or 14 years old during some school bucket list project. On there was save a life and I got to cross it off so thats pretty cool."

Her life-saving match-- 33-year-old father of six from Mesa, Mark Roser. Roser learned he had ALL after breaking a hip and feeling increasingly weak in 2018.

He needed a bone marrow transplant to survive. He says, "When they discovered it, 94% of my blood cells basically contaminated, so I was really at the final deadline."

Gift of Life Marrow Registry matched the Jennie to Mark with months.

The pair met for the first time at Boca Oyster Bar in Bridgeport in October. Mark says, " I feel great. Im much more positive between work and family. My priorities have completely changed. Time with the kids, time with my wife, just being there for them instead of working so much... I treasure every moment with them now."

According to the gift of Life marrow registry website: "Blood cancer is an umbrella term for cancers that affect the blood, bone marrow and lymphatic system. In most blood cancers, normal blood cell development is interrupted by uncontrolled growth of abnormal blood cells. The abnormal blood cells can prevent blood from fighting off infection or preventing uncontrolled bleeding.

Unfortunately, blood cancer can strike any one of us at any time. Approximately every three minutes, a child or adult in the United States is diagnosed with a type of blood cancer. Thats 360 people a day, 130,000 people a year.

There are three main types of blood cancers: Leukemia, cancer that is found in your blood and bone marrow; Lymphoma, blood cancer that affects the lymphatic system; and Myeloma, blood cancer that specifically targets your plasma cells.

For many, there is hope of a cure through a bone marrow or peripheral blood stem cell transplant. Today, transplantation, of healthy stem cells donated by related and unrelated volunteers, offers hope to many patients suffering from these sometimes deadly diseases.

Advances in transplantation have made this procedure a reality for thousands who are alive today because a stranger gave them the Gift of Life!."

check out: https://www.giftoflife.org to learn more and even register for a swab kit and become a donor yourself.

Follow this link:
Redding woman donates bone marrow, saves life of a father - FOX61 Hartford

Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) – Smarter Analyst

Maxim Group analyst Jason McCarthy maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI) yesterday and set a price target of $9.00. The companys shares closed last Monday at $3.70.

According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -22.0% and a 25.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brainstorm Cell Therapeutics with a $9.00 average price target.

See todays analyst top recommended stocks >>

The company has a one-year high of $4.50 and a one-year low of $2.92. Currently, Brainstorm Cell Therapeutics has an average volume of 52.25K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCLI in relation to earlier this year. Most recently, in August 2019, Irit Arbel, a Director at BCLI sold 13,332 shares for a total of $48,795.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinsons disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

More:
Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) - Smarter Analyst

How 3D Printing Is Turning Each And Every Industry On Its Head – SafeHaven.com

Calling all carnivores: ever thought about getting a meat printer? Of hand-crafting delectable beef steaks at home from plant proteins, that have the same texture, appearance, and flavor as real meat, only without the distasteful killing part?

3D-printed steaks and chicken could be on the menu in European restaurants as early as 2020, with home-spun meat printers available to the consumer within a few more years. Israel-based Redefine Meat is already using advanced food formulations along with proprietary 3D printing technology to make what it calls the holy grail of alt-meat,reports Tech Radar Pro.

The idea sounds absurd, but its not so far-fetched, as three-dimensional printing technology goes in directions no-one could dream of, prior to the launch of 3D printing in the 1980s.

Uses

Put simply, 3D printing is a progression of 2D printing, where a third dimension is added to the printing of images on a flat surface (a regular ink-jet printer), adding depth and allowing the printer cartridge to move in all directions. A digital file is first created using modeling software, then sent to the printer, depositing layers of the chosen material - often plastic or wax - to build up the final product. Other printing materials include plastics, powders, filaments, paper, and even human or animal cells - used in the cutting-edge new field of bioprinting.

3D printing is also referred to as additive manufacturing because objects are made by injection-molding them to the desired size and shape, versus traditional manufacturing which invariably entails loading material into a machine to be cut to the required dimensions. With additive manufacturing, material is added, layer upon layer, without creating waste/ scrap.

3D Printer employs agood analogy for 3D printing, describing the process as similar to baking a multi-layered cake:

3D printers use a variety of very different types of additive manufacturing technologies, but they all share one core thing in common: they create athree dimensionalobject by building it layer by successive layer, until the entire object is complete. Its much like printing in two dimensions on a sheet of paper, but with an added third dimension: UP. The Z-axis.

Each of these printed layers is athinly-sliced, horizontal cross-section of the eventual object. Imagine a multi-layer cake, with the baker laying down each layer one at a time until the entire cake is formed. 3D printing is somewhat similar, but just a bit more precise than 3D baking.

Formerly known as stereolithography, 3D printing was invented in 1983 by Chuck Hull, co-founder of 3D Systems. Frustrated by how long it took to make small, custom parts, Hull suggested using his furniture companys UV lamps to create parts by curing photosensitive resin, layer by layer. Calling the technology stereolithography, Hull applied for a patent and was issued one in 1986.

Two years later, start-up 3D Systems manufactured the first 3D printer, the SLA-1.

It took over 30 years for the technology to become mainstream, but now 3D printing can be done by anyone with access to a base-model 3D printer, which can be purchased for under $500.

Among the more interesting items that have been 3D-printed are prosthetic limbs, fabricated firearms, electrical vehicles, steel parts (Caterpillar introduced thefirst 3D-printed excavatorin 2017), quick-build homes, parts for combat aircraft, spacecraft, and even decorative chocolates.

Relativity Space is 3D-printing rockets at its Los Angeles headquarters.

According to Wired,youll find four of the largest metal 3D printers in the world, churning out rocket parts day and night. The latest model of the companys proprietary printer, dubbed Stargate, stands 30 feet tall and has two massive robotic arms that protrude like tentacles from the machine. The Stargate printers will manufacture about 95 percent, by mass, of Relativitys first rocket, named Terran-1. The only parts that wont be printed are the electronics, cables, and a handful of moving parts and rubber gaskets.

Z-Morph Bloglists five more really cool, recently-printed 3D-printed objects:

Methods

From its mid-80s beginning, a number of 3D printing technologies have emerged.

The first, known asStereolithography (SLA), concentrates a beam of ultraviolet light onto the surface of a vat filled with liquid photocurable resin. The laser beam draws out the 3D model one layer at a time, with each slice hardening as the light hits the resin. The solidified structure is gradually dragged up by a lifting platform, while the laser continues to form a different pattern for each layer to create the desired shape of the object.

Digital Light Processing (DLP)is similar toStereolithography, butuses more conventional light sources. A liquid crystal display allows for a large amount of light to be projected onto the surface of the object being printed, and for the resin to harden quickly.

Fused Deposition Modeling (FDM)was invented in the late 1980s. The object is made by extruding a stream of melted thermoplastic material to form layers. The layers harden and fuse together almost immediately after leaving the extrusion nozzle.

InSelective Layer Sintering (SLS), powdered materials instead of liquid photopolymer is drawn from the vat, including polystyrene, ceramics, glass, nylon and metals such as steel, titanium, aluminum and silver. A layer of powdered material is placed on top of the previous layer using a roller and then the powdered material is fused or sintered according to a certain pattern.

PolyJetphotopolymershoots out a photopolymer liquid, similarly to an ink-jet printer, which is hardened with a UV light. This technology acquired by Stratasys allows for various materials and colors to be incorporated into single prints, and at high resolutions.

WithSyringe Extrusion, virtually any material with a creamy viscosity such as clay, cement or silicone, can be 3D-printed using syringe extruders. The syringe is heated or not heated, depending on the material.

Other variants of these technologies includeSelective Laser Melting (SLM),Electron Beam Melting (EBM)which uses an electron beam instead of a laser, andLaminated Object Manufacturing (LOM), where layers of paper, plastic or metal, coated with adhesive, are successively glued together and cut to shape.

Market

Sales related to 3D printing, including printers, materials and services, will move past $US2.7 billion in 2019 and hit $3 billion in 2020according to Deloitte Global, with a CAGR of 12.5%. Comparing that to the $12 trillion in global manufacturing revenues indicates the amount of growth potential in 3D printing and bioprinting.

The consulting firm explains that companies across multiple industries are increasingly using 3D printing for more than just rapid prototyping:

3D printers todayare capable of printinga greater variety of materials (which mainly means more metal printing and less plastic printing, although plastic will likely still predominate); they print objects faster than they used to, and they can print larger objects (build volume). A steady stream of new entrants is expanding the market. 3D printing is considered an essential ingredient in Industry 4.0, the marriage of advanced production and operations techniques with smart digital technologies that is being heralded as the Fourth Industrial Revolution.

Deloitte notes the number of materials used in 3D printing has more than doubled from five years ago, with mixed-material printers becoming more common. 3D printers are also about twice as fast in 2019 as they were in 2014.

It says the biggest shift is from plastic to metal printing: Plastic is fine for prototypes and certain final parts, but the trillion-dollar metal-parts fabrication market is the more important market for 3D printers to address. Plastics share of the 3D printing industry fell from 88 to 65% in 2017-18, and metal rose from 28 to 36%.

A recent technology called binder jet metal printing could halve the time required to produce each part, compared to the relatively slow and expensive selective laser sintering (SLS) method, states Deloitte.

Size capabilities are improving too. A few yearsagoa high-end metal printer could only build an object 10x10x10 cm or one cubic liter. In 2019 metal printers with the capacity to print 30x30x30 cm are available.

Companies

As 3D printing technology continues to advance, more and more companies are forming, eager to get in on the action. Three of the largest are Stratasys, 3D Systems and Proto Labs; these companies offer 3D printers and services to help manufacturers move prototypes into production.

Based in Minnesota,Stratasyshas over 600 granted or pending additive manufacturing patents, including for the FDM,Polyjetand WDM 3D printing technologies. Among the sectors Stratasys serves are healthcare, aerospace, automotive and education. The companyssubsidiaries include MakerBot,GrabCAD,RedEyeOnDemand and Solid Concepts.

Asmentioned3D Systemswas first out of the gate with a 3D printer, back in 1988. Along with pioneering stereolithography, 3D Systems has also developed selective laser sintering, multi-jet printing, film-transfer imaging, color jet printing, direct metal printing, and plastic jet printing. Divided into three business units - products, materials and services - 3D Systems offers small desk-top printers, metal printers and commercial printers that print in plastics and other materials.

Also headquartered in Minnesota isProto Labs, established in 1999. Building on automated solutions to develop plastic and metal parts used in manufacturing, in 2014 Proto Labs launched an industrial-grade 3D printing service, enabling software developers and engineers to quickly move prototypes into production. The company acquired Rapid Manufacturing in 2017 to further its efforts in sheet metal fabrication. It currently has 2,300 employees in 12 manufacturing hubs.

3D bioprinting - the next big thing in medical investing

According to the United Network for Organ Sharing, every day 21 people in the United States die waiting for an organ, and over 120,000 people are on organ transplant waiting lists.

Related: Will Bezos Buy The Seattle Seahawks?

The situation is worse in Canada. While Spain has 43 donors per million people, the US has 26, Britain has 21, and Canada has just 20. Out of 4,500 Canadians waiting for an organ, about 260 will die each year, according toThe Organ Project. Thats five deaths per week.

Imagine if, instead of waiting for an organ from another person - possibly a relative but likely a stranger - you could walk into a doctors office and have one manufactured, with your cells. It sounds far-fetched, but the technology now exists for the tailor-made transplantation of organs through brand-new medicine called 3D bioprinting.

What is 3D bioprinting?

3D printing is a progression of 2D printing, where a third dimension is added to the printing of images on a flat surface (a regular ink-jet printer), adding depth and allowing the printer cartridge to move in all directions. A digital file is first created using modeling software, then sent to the printer, depositing layers of the chosen material - often plastic or wax - to build up the final product.

Among the more interesting items that have been 3D-printed are prosthetic limbs, fabricated firearms, electrical vehicles, steel parts (Caterpillar introduced thefirst 3D-printed excavatorin 2017), quick-build homes, parts for combat aircraft and spacecraft, and even decorative chocolates.

Bioprinting operates on the same principle as regular 3D printing but instead of plastic, wax or other matter, bioprinters deposit layers of living cells to build structures like blood vessels or skin tissue. The cells are taken from an animal or a human being and cultivated until there are enough to create bio-ink which is then loaded into the printer using mechanical syringes. Adult stem cells can also be utilized.

Key to the process is a dissolvable gel which acts as a kind of incubator for the cells to multiply - like an embryo growing in a womb. Researchers may also plant cells around 3D scaffolds made of biodegradable polymers or collagen, allowing them to develop into functional tissue. The cells use their inherent properties to seek out similar cells to join with. Researchersare able tocontrol the shape into which the cells form, and the printer builds the final structure.

After the tissues are fully grown and shaped, they are placed into a recipients body. The hope is that the 3D-printed object becomes as much a part of the patients body as the cells he or she was born with.

There are currently five common methods of 3D bioprinting:

- Inkjet bioprinting: Droplets of bio-ink are deposited, layer by layer, onto a culture plate. Cells that can help fight breast cancer have been successful printed using inkjet bioprinting.

- Extrusion bioprinting: Polymer or hydrogel is loaded in syringes and dispensed via pneumatic- or screw-driven force, onto a building platform. The motion is controlled by a computer. Extrusion bioprinting offers lower resolution than inkjet bioprinting but the fabrication speed is considerably higher, allowinganatomically-shapedobjects to be generated.

- Laser-assisted bioprinting: A laser is used to deposit the biomaterials into a receptor via a tape covered with biological material. The laser irradiates the tape, causing the biological material to evaporate and reach the receptor in the form of droplets. The droplets contain a biopolymer that acts as an adhesive to help the cells to grow. This high-resolution bioprinting method is being used in a partnership between French bioprinting companyPoietisand LOral to recreate a hair follicle that could lead to a cure for baldness.

- Stereolithography: Stereolithographic bioprinting uses a digital micro-mirror to direct ultraviolet light onto the printing surface. Light directed by the micro-mirrors triggers the formation of molecular bonds, which cause light-sensitive hydrogels to form into solid material.

- Bioprinting with acoustic waves: Using a device that allows cells to be manipulated with acoustic waves, researchers can manipulate where the waves will meet along three axes. The waves then form a trap that captures the cells, which are collected to create 3D patterns.

How far has it progressed?

Some of the most advanced work on bioprinting has been done at the Wake Forest Institute for Regenerative Medicine in California. One of the first major structures that Wake Forestbioprintedwas a human bladder. Made from cells extracted from a patient with a poor-functioning bladder, the 3D-printed bladder was successfully transplanted. The project built on custom-grown bladders that had previously been transplanted into seven patients suffering from spina bifida, a birth defect that affects the spinal cord.

Wake Forest staffers have also created an outer human ear, and implantedbioprintedskin, bone and muscle on laboratory animals that successfully grew into surrounding tissue.

The institutes director, AnthonyAtala, sees bioprinting astotalytransforming the relationship between the transplant patient and doctor, in much the same way that Dell changed the way consumers interacted with the computer company that sold PCs tailored to each customers unique needs. Patients could order replacement parts in much the same way they might order a new clutch for their Mazda.

Youd have companies that exist to process cells, create constructs, tissue. Your surgeon might take a CT scan and a tissue sample and ship it to that company,Atalasaid in afeature article on bioprinting in Smithsonian Magazine.

The company would then ship the organ back a week or so later, ready for implantation. Welcome to the new world of regenerative medicine: the plug and play human body.

Related: Ousted Uber CEO Cashes Out $500 Million In Stock

Atalasaid the technology is developing to the point where researchers are almost able to replicate simple organs like the outer ear and the trachea (windpipe). Importantly, there are no real surgical challenges, he told Smithsonian.

Challenges

The holy grail of 3D bioprinting would be to come up with a viable kidney for transplant. ProfessorAtala, of the Wake Forest Institute, created the first small-scalebioprintedkidney in 2002. However,Atalais the first to admit that his machine-produced kidney is nowhere near at the level it needs to be for a human transplant. A TED TalkAtalagave in 2011 about bioprinting, which culminated with a dramatic display of an object - really an over-sized bean - became controversial when the press gotaholdof it and printed enthusiastic, but wrong, stories about the technology eliminating the need for a kidney transplant.

Another potential roadblock is the cost. No-one yet knows what it would cost tobioprintand transplant a human organ on demand, and how accessible the procedure would be to the masses of patients requiring a transplant. And while there have been successful bioprinted organ transplants, there havent been enough to determine how well the human body will accept the new tissue or artificial organ.

Finally, one shouldnt underestimate the complexity and level of difficulty involved. Aspharmaforumpoints out, A complex network of cells, tissues, nerves and structures in a human organ need to be correctly positioned with a highest precision for it to function properly. From arranging the thousands of tiny capillaries in a liver, to printing a heart that beats, it is a long, difficult process.

Skin

Wake Forest is working on a skin-cell printer capable of printing live skin cells directly onto a burn wound. The procedure could replace skin-grafting, a procedure where healthy skin is harvested from an unburnt part of a patients body. Skin grafting can be hard to heal from, and in severe burn cases, there isnt enough healthy skin left to use.

This new printing technique only needs a patch of skin 10% the size of the burn, that is used to grow enough cells for 3D printing. The wound is then scanned for size and depth, information which the printer uses to print skin cells at the proper depths to cover the wound.

In 2017 scientists in Madrid created a prototype of a 3D bioprinter that can create functional human skin. The printer is adequate for transplanting skin and for testing cosmetic, chemical and pharmaceutical products,ScienceDaily reported.

Hearts

At the Texas Heart Institute in Houston, researchers are working with decelluarized pig hearts. The organs have been stripped of muscle and other living tissue, but the original architecture is intact. The idea is to use decelluarized pig hearts, repopulated with bioprinted human cells, for implantation into humans. Sofarthe institute has succeeded in injecting pig hearts with living bovine cells, then inserted them into cows where they worked successfully next to a cows heart.

Already, patients with a defective heart valve can have a pigs valve or a mechanical valve implanted. Doris Taylor, director of the institutes regenerative medicine research program, says thedecelluarizedmethod gets around the tricky process of printing at the extremely high resolution required for highly vascularized (containing many blood vessels) organs like the heart.

The tech is going to have to improve a great deal before were able tobioprinta kidney or a heart, and get blood to it, and keep it alive, Taylor told Smithsonian.

More recent developments though are moving in that direction. In 2016 Harvard researchers 3D-printed the first heart-on-a-chip. The tiny device contains living human heart cells that mimic the hearts functions.

In 2018, 3D printingstartupBioLife4D successfully produced human tissue in the form of a cardiac patch - derived from a patients white blood cells with multiple cell types contained in the human heart.According to pharmaforum, its another step towards bioprinting major organs for transplant.

Scientists at the American Friends of Tel Aviv University havereportedly 3D-printed a fully-vascularized heartusing fat cells from a donor. The fat cells were partially cultured and re-programmed into heart cells. This early-stage technology has only been able to print a heart the size of a rabbits, but researchers hope to test the printed hearts in other animals.

Ovaries

Northwestern University in Illinois debuted a 3D-printed ovary using the acoustic waves method described above, and in Sweden, researchers have successfully created human cartilage tissue, also using acoustic waves.

Thyroids

Russian scientists aboard the International Space Stationsuccessful bioprinted the first organ in space: a mouses thyroid. Spaces zero-gravity environment enables organs and tissues to mature faster than on Earth.

Bones/ cartilage

A team from the UKs Swansea University has apparently developed a bioprinting process that uses regenerative material to create an artificial bone matrix. The technology could replace bone grafting, a surgical procedure that replaces missing or damaged bones with synthetic materials. Unlike bone grafting, which doesnt allow new bone tissues to form, thus limiting mechanical integrity, 3D-printed bones are capable of fusing with, and even replacing over time, a patients natural bones.

Cartilage printing could revolutionize joint care through a hand-held cartilage printing device calledBioPen. Built by Australian researchers, theBioPencontains stem cells derived from a patients fat, which create custom scaffolds of living material into failing joints much like 3D-printed bones. So farBioPenhas only been tested on sheep but developers plan to accelerate it to regenerate functional human cartilage.

Corneas

Finally, a group of researchers in South Korea has 3D-printed prototype corneas fromdecelluarizedcorneal stroma and stem cells. Unlike artificial corneas currently available, made of substances like synthetic polymer which resist incorporation into the eye, printed corneas are made to mimic the material within natural corneas. The invention could replace the need for donors and synthetic corneas in cataract surgery and other sight complications.

Investment opportunity

3D bioprinting has come a long way since ProfessorAtalasfirst artificial bladder in 2002. At Ahead of the Herd, we think it is the next big thing in regenerative medicine. Science always starts out with experimentation, sometimes many years of it, before the technologies are commercialized. We want our subscribers to bewell awareof 3D bioprintings potential, putting them in a position to get in early to companies that are offeringbioprintedproducts.

While there are currently a handful of bioprinting firms, we see an entire ecosystem of small firms developing, with each focusing on a different aspect, technology or part of the body. It will not take 10 years for start-up pub-cos to IPO, seeking money to develop their technologies.

Currently valued at USD$685 million, within the next six years,the global bioprinting market is expected to expand by a CAGR of 26.2%, reaching $4.4 billion by 2026. The United States and Canada are the industry leaders, making bioprinting an ideal new sector for North America-focused investors.

Go here to see the original:
How 3D Printing Is Turning Each And Every Industry On Its Head - SafeHaven.com

BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders – Market Exclusive

BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.

On November 13, 2019, BioRestorative Therapies, Inc. (the Company) held a Special Meeting of Stockholders (the Special Meeting). The following is a listing of the votes cast for and against, as well as abstentions, with respect to the matters voted upon at the Special Meeting. At the Special Meeting, the Companys stockholders (i) approved an amendment to the Companys Certificate of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 150,000,000 to 300,000,000, (ii) approved amendments to the Certificate of Incorporation of the Company, and authorized the Board of Directors of the Company to select and file one such amendment, to effect a reverse stock split of the Companys common stock at a ratio of not less than 1-for-2 and not more than 1-for-100, with the Board of Directors of the Company having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Companys Board of Directors in its discretion (the Reverse Stock Split Proposal), which Reverse Stock Split Proposal revises the reverse stock split ratio approved by the Companys stockholders on May 30, 2019 and (iii) authorized the Board of Directors of the Company, in its discretion, to reduce the number of shares of common stock authorized to be issued by the Company in proportion to the percentage decrease in the number of outstanding shares of common stock resulting from the reverse split (or a lesser decrease in authorized shares of common stock as determined by the Companys Board of Directors in its discretion).

(d) Exhibits.

3.1 Certificate of Amendment of Certificate of Incorporation of the Company

About BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX)

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem). Its curved needle device (CND) is a needle system with a curved inner cannula to allow access to difficult-to-locate regions for the delivery or removal of fluids and other substances. The CND is intended to deliver stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or other areas of the body. The device relies on the use of pre-curved nested cannulae that allows the cells or material to be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures.

Read more:
BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders - Market Exclusive

Global Cell Expansion Market 2019 is predicted to reach an excellent valuation of by 2024 – Galus Australis

According to this Cell Expansion report, the key market players are making moves like product launches, joint ventures, developments, mergers and acquisitions which has influence on the market and healthcare Industry as a whole and also affecting the sales, import, export, revenue and CAGR values.

With Cell Expansion Market report you can build a strong organization and make better decisions that take your business on the right track. This report is a valuable source of assistance for companies and individuals that offers industry chain structure, business strategies and proposals for new project investments. This report introduces top to bottom evaluation of the Healthcare industry including empowering technologies, key trends, market drivers, challenges, standardization, regulatory landscape, opportunities, future guide, value chain, ecosystem player profiles and strategies. This industry analysis report speaks in detail about the manufacturing process, type and applications.

Some of the eminent industry players operating in Cell Expansion Market are BD, Merck KGaA, TERUMO BCT, INC., Lonza, Beckman Coulter, Inc., Cyto-Matrix Inc., ReNeuron Group plc, pluristem, NexImmune, RepliCel, TC BioPharm, GE Healthcare, Thermo Fisher Scientific, Inc., Corning Incorporated, Miltenyi Biotec, STEMCELL Technologies Inc., Danaher, CellProthera and others

The Global Cell Expansion Market is accounted for USD 11.43 billion and market is growing at a CAGR of 17.8% by the end of 2024.

Interested in getting the full Sample Report? Here You Can Access @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-cell-expansion-market

Cell expansion which deals with the production of cells from single cell, is used in therapeutic development, drug screening, and microlevel research of cells. Recently, cell expansion is widely used for improving transplantation and in the treatment of various diseases including rheumatoid arthritis, diabetes, and others.

The increasing prevalence of chronic diseases combined with the increase in research activities are the main factors driving the market for cellular expansion. Furthermore, technological advances in cellular expansion devices and the growth of public healthcare investment are the factors driving the market for cellular expansion. Furthermore, it is expected that even economic tools for cell-based research will promote the market for cell expansion during the forecast period.

The global cell expansion market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cell expansion market for global, Europe, North America, Asia Pacific and South America.

Key Segmentation of Global Cell Expansion Market

By product, global cell expansion market is segmented into

consumables and

instruments

Consumables are further sub segmented into reagents, media, & serum and disposables.

Disposables are again sub segmented into bioreactor accessories, tissue culture flasks and others.

Instruments are segmented into cell expansion supporting equipment, bioreactors and automated cell expansion systems.

Cell Expansion Supporting Equipment can be further sub segmented into flow cytometers, centrifuges, cell counters and others.

Bioreactors can be further sub segmented into perfusion bioreactors and microcarrier bioreactors.

Microcarrier Bioreactors can be sub segmented into anchorage-dependent and anchorage independent.

On the basis of application, global cell expansion market is segmented into

regenerative medicine,

stem cell research,

oncology and

cell-based research and others

On the basis of cell type, global cell expansion market is segmented into

human cells and

animal cells

Human cells can be further sub segmented into stem cells and differentiated cells. Stem cells are sub segmented into adult stem cells, embryonic stem cells and induced pluripotent stem cells.

Based on end user, global cell expansion market is segmented into

pharma & biotech companies,

research institutes,

cell banks and others

On the basis of geography, global cell expansion market report covers data points for 28 countries across multiple geographies such as

North America & South America,

Europe,

Asia-Pacific, and

Middle East & Africa

Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.

Place purchase order for Global Cell Expansion Market at https://databridgemarketresearch.com/checkout/buy/enterprise/global-cell-expansion-market

Table of Contents: Global Cell Expansion Market

Major Highlights of TOC:

Chapter One: Cell Expansion Market Industry Overview

1.1 Cell Expansion Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Cell Expansion Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Cell Expansion Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Cell Expansion Market Size by Demand

2.3 Cell Expansion Market Forecast by Demand

Chapter Three: Cell Expansion Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Cell Expansion Market Size by Type

3.3 Cell Expansion Market Forecast by Type

Chapter Four: Major Region of Cell Expansion Market

4.1 Cell Expansion Sales

4.2 Cell Expansion Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Get TOC at https://databridgemarketresearch.com/toc/?dbmr=global-cell-expansion-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

See original here:
Global Cell Expansion Market 2019 is predicted to reach an excellent valuation of by 2024 - Galus Australis

Stem Cell Assay Market is Growing Massively in Upcoming Year with Top Key Players like GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell…

Stem cells refer to the undifferentiated biological cells that differentiate into specialized cells and divide to produce more stem cells. They are found in multicellular organisms and are of two types mainly embryonic stem cells and adult stem cells. Stem cell assays involve the technique of analyzing living cell on the basis of different parameters such as shape, size, and others. These assays are used to measure biochemical and cellular functions using functional cells as diagnostic tools in the research of new drugs. Stem cell assays are also used to measure cell proliferations, motility, and toxicity.

Stem Cell Assay Market report explains the competitive analysis of the top leading key players with the with key success factors for newcomers in the global market. The Stem Cell Assay report provides the historical growth of the largest countries in every region, which allows the reader to make effective long-term investment decisions.

For Sample Copy of this Report@:

https://healthcareintelligencemarkets.com/request_sample.php?id=29100

Top Key Players are including in this report: GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs Inc., Hemogenix Inc., STEMCELL Technologies Inc., Bio-Rad Laboratories Inc, Bio-Techne Corporation, Cellular Dynamics International Inc., Promega Corporation. Etc.

Market by Type:

Market by Application:

Factors that are expected to influence this global market are the rising employment rate among investments in emerging economies are mentioned in the report. Export incentives offered by several competitive nations and robust trade agreements are other factors that also favor the growth rate in the global market for Stem Cell Assay industry.

To Avail the Discount on this Report@:

https://healthcareintelligencemarkets.com/ask_for_discount.php?id=29100

The key questions answered in the report:

Across the globe, different regions such as North America, Latin America, Asia-Pacific, Europe, and Africa have been examined on the basis of productivity and manufacturing base. Researchers of this report throw light on different terminologies.

As per the findings of the report, Stem Cell Assay is a product generated by processing many high advanced technologies. This application is found in several products. The report has discovered that the Stem Cell Assay market is marked by several segments.

For More Information, Visit @:

https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=29100

Table of Contents

Global Stem Cell Assay Market Research Report

Chapter 1 Stem Cell Assay Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

.. TOC Continued.

Read more:
Stem Cell Assay Market is Growing Massively in Upcoming Year with Top Key Players like GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell...